ClinicalTrials.Veeva

Menu

Study of Human Leukocyte Antigen (HLA) Polymorphisms in Patients With Rheumatoid Arthritis (HLAPRPA)

U

University Hospital Center of Martinique

Status

Completed

Conditions

Rheumatoid Arthritis

Treatments

Biological: Collect of 10 ml of peripheric blood for DNA extraction

Study type

Observational

Funder types

Other

Identifiers

NCT01111357
09/B/02

Details and patient eligibility

About

Rheumatoid arthritis (RA), affects between 0.3% and 1.0% of the population, it can lead to progressive joint destruction and severe disability. To date, two RA genetic susceptibility factors have been identified: HLA-DRB1-SE (Shared epitope) and PTPN22 620W alleles. The predictive value of the alleles for diagnosis of RA was previously investigated in cohorts of caucasians patients with early unclassified arthritis that showed restrained association between RA and HLA-SE. Despite the contribution of HLA to the overall genetic risk has been estimated to range from 30% to 50%, it has never been studied in the French west-Indian population.

Enrollment

200 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Diagnosis of Rheumatoid Arthritis according to ACR criteria
  • Come from French West Indies (At least 3 grandparents are African-Caribbean)
  • Sign written informed consent

Exclusion criteria

  • Minor
  • Patient with no Rheumatoid Arthritis according to ACR criteria
  • Patient does not agree for a genetic study

For the control

Inclusion Criteria:

  • Blood donor
  • Sign written informed consent
  • Patient with no Rheumatoid Arthritis according to ACR criteria
  • Come from French West Indies (At least 3 grandparents are African-Caribbean)

Exclusion Criteria:

  • Minor
  • Patient does not agree for a genetic study

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems